Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: David Bogdanoff who wrote (20033)	5/4/1998 9:44:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

David, There are side effects associated with the inhibitors (I think that bleeding was one of them). I also expect the argument that since normal cells are targeted, there will not be resistance. Although Nixon declared war on cancer over 25 years ago, the battle has been fought at the molecular level for 100's of millions of years. A good example is the ability of the primary tumors to inhibit metastatic tumors from growing. If drugs reduce blood supply, then there is selection for tumors that can grow with a reduced blood supply. BBIOY went from low double digits to triple digits in a day and most remarkably, their drug was targeting angiogenesis. BBIOY has definitely come down to earth and I expect a similar retreat by ENMD.